Official Title
The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients
Brief Summary
This study intended to evaluate the effects of commonly used diuretic, spironolactone, on oxygenation in covid-19 ARDS patients.
Completed
Respiratory Distress Syndrome, Adult
Drug: Spironolactone 100mg
2x100 mg spironolactone for 5 consecutive days
Drug: Placebo oral tablet
2 x1 placebo tablet
Eligibility Criteria
Inclusion Criteria:
- Hemodynamically stable
- Hypoxemia, i.e. p/f <150
- Admitted to ICU within 48 hours
- Not moribund has a life expectancy greater than 24 hours
Exclusion Criteria:
- Age criteria
- Pregnancy
- Unwillingness to participate
Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Turkey
Locations
Istanbul University-Cerrahpaşa
Istanbul, Turkey
Yalim Dikmen, Study Director
Prof
Istanbul University - Cerrahpasa (IUC)
NCT Number
MeSH Terms
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Spironolactone